Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free DXCM Stock Alerts $138.70 -0.78 (-0.56%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$138.52▼$140.8050-Day Range$114.22▼$140.1052-Week Range$74.75▼$142.00Volume2.52 million shsAverage Volume3.12 million shsMarket Capitalization$53.47 billionP/E Ratio105.88Dividend YieldN/APrice Target$136.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get DexCom alerts: Email Address DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside1.5% Downside$136.67 Price TargetShort InterestHealthy4.12% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.91Based on 20 Articles This WeekInsider TradingSelling Shares$24.02 M Sold Last QuarterProj. Earnings Growth26.70%From $1.76 to $2.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.32 out of 5 starsMedical Sector155th out of 938 stocksSurgical & Medical Instruments Industry17th out of 94 stocks 1.5 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $136.67, DexCom has a forecasted downside of 1.5% from its current price of $138.70.Amount of Analyst CoverageDexCom has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.12% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in DexCom has recently decreased by 4.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 2.7 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for DexCom this week, compared to 12 articles on an average week.Search InterestOnly 39 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 31 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -9% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,020,621.00 in company stock.Percentage Held by InsidersOnly 0.41% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 26.70% in the coming year, from $1.76 to $2.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 105.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.97.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 105.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 270.19.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 25.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesMarch 27, 2024 | insidertrades.comDexCom, Inc. (NASDAQ:DXCM) EVP Sells $579,180.00 in StockMarch 16, 2024 | insidertrades.comJereme M. Sylvain Sells 11,661 Shares of DexCom, Inc. (NASDAQ:DXCM) StockMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 27, 2024 | finance.yahoo.comDiabetes Play Dexcom Tops Buy Point After FDA Clears Device Likely To Be Used For Weight LossMarch 27, 2024 | finance.yahoo.comDexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.March 27, 2024 | finance.yahoo.comDexCom (DXCM) Stock Moves -0.12%: What You Should KnowMarch 27, 2024 | finance.yahoo.comInsider Sell: EVP Chief Human Resources Sadie Stern Sells 4,137 Shares of DexCom Inc (DXCM)March 27, 2024 | finance.yahoo.comHere’s What Happened to Dexcom (DXCM) Stock in Q4March 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 27, 2024 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern Sells 4,137 SharesMarch 27, 2024 | americanbankingnews.comDexCom (NASDAQ:DXCM) Downgraded by StockNews.com to HoldMarch 25, 2024 | investorplace.comMore Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy'March 25, 2024 | gurufocus.comWhat's Driving DexCom Inc's Surprising 14% Stock Rally?March 23, 2024 | finance.yahoo.comIs DexCom, Inc.'s (NASDAQ:DXCM) 26% ROE Better Than Average?March 20, 2024 | finance.yahoo.com25 Countries With Limited Access To HealthcareMarch 20, 2024 | benzinga.comDexCom's Options: A Look at What the Big Money is ThinkingMarch 20, 2024 | finance.yahoo.comShould You Hold DexCom (DXCM) for the Long Term?March 19, 2024 | finance.yahoo.comInsider Sell: EVP Strategy & Corporate Development Matthew Dolan Sells Shares of DexCom Inc ...March 18, 2024 | finance.yahoo.comDexCom Stock Trying To Close In On Key Technical BenchmarkMarch 17, 2024 | finance.yahoo.comDexCom Insiders Sold US$18m Of Shares Suggesting HesitancyMarch 16, 2024 | finance.yahoo.comDXCM Mar 2024 126.000 callMarch 14, 2024 | finance.yahoo.comDXCM Mar 2024 149.000 putMarch 13, 2024 | finance.yahoo.comIBD Stock Of The Day Dexcom Lingers In Buy Zone As Diabetes Play Eyes Obesity MarketMarch 12, 2024 | markets.businessinsider.comDexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst SaysMarch 11, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Dexcom (DXCM)March 9, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)March 9, 2024 | finance.yahoo.comDXCM Mar 2024 116.000 putSee More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today3/28/2024Next Earnings (Estimated)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$136.67 High Stock Price Target$165.00 Low Stock Price Target$100.00 Potential Upside/Downside-1.5%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$1.31 Trailing P/E Ratio105.88 Forward P/E Ratio78.81 P/E Growth2.4Net Income$541.50 million Net Margins14.95% Pretax Margin19.61% Return on Equity28.31% Return on Assets9.74% Debt Debt-to-Equity Ratio1.18 Current Ratio2.84 Quick Ratio2.48 Sales & Book Value Annual Sales$3.62 billion Price / Sales14.76 Cash Flow$2.05 per share Price / Cash Flow67.62 Book Value$5.35 per share Price / Book25.93Miscellaneous Outstanding Shares385,520,000Free Float383,934,000Market Cap$53.47 billion OptionableOptionable Beta1.18 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 66)Executive Chairman, CEO & President Comp: $2.22MMr. Jereme M. Sylvain (Age 44)Executive VP, CFO & Chief Accounting Officer Comp: $841.14kMr. Jacob Steven Leach (Age 46)Executive VP & COO Comp: $994.13kMr. Girish Naganathan (Age 47)Executive VP & CTO Comp: $423.92kMr. Michael Jon Brown (Age 54)Executive VP & Chief Legal Officer Comp: $954.46kMr. Shelly Ramasamy Selvaraj (Age 65)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 43)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne MarshExecutive Vice President of MarketingMs. Sadie M. Stern (Age 49)Executive VP & Chief Human Resources Officer More ExecutivesKey Competitors3MNYSE:MMMBecton, Dickinson and CompanyNYSE:BDXResMedNYSE:RMDBaxter InternationalNYSE:BAXAbiomedNASDAQ:ABMDView All CompetitorsInsiders & InstitutionsNewbridge Financial Services Group Inc.Bought 132 shares on 3/28/2024Ownership: 0.001%HighPoint Advisor Group LLCBought 3,606 shares on 3/26/2024Ownership: 0.001%Sadie SternSold 4,137 sharesTotal: $579,180.00 ($140.00/share)PNC Financial Services Group Inc.Bought 3,823 shares on 3/22/2024Ownership: 0.012%B. Riley Wealth Advisors Inc.Sold 2,143 shares on 3/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy DexCom Stock? DXCM Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in DexCom, Inc.: DexCom has shown consistent growth in institutional investor holdings, indicating confidence in the company's future prospects. The company's stock price has been on an upward trend, reflecting positive market sentiment and potential for further gains. Analysts have provided favorable ratings and price targets for DexCom, suggesting a positive outlook for the stock. DexCom's innovative medical devices have a strong market demand, positioning the company well for future revenue growth. Recent acquisitions and partnerships by DexCom have expanded its market reach and product offerings, enhancing its competitive position. Cons Investors should be bearish about investing in DexCom, Inc. for these reasons: Despite positive analyst ratings, there may be risks associated with potential market fluctuations affecting the stock price. Competition in the medical device industry is intense, which could impact DexCom's market share and profitability. Regulatory challenges and changes in healthcare policies could pose risks to DexCom's operations and financial performance. Dependency on a few key products for revenue generation exposes DexCom to risks related to product obsolescence or market saturation. Market volatility and macroeconomic factors could influence investor sentiment towards DexCom, leading to fluctuations in the stock price. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com. DXCM Stock Analysis - Frequently Asked Questions Should I buy or sell DexCom stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price target for 2024? 14 brokerages have issued 12 month target prices for DexCom's stock. Their DXCM share price targets range from $100.00 to $165.00. On average, they expect the company's share price to reach $136.67 in the next year. This suggests that the stock has a possible downside of 1.5%. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2024? DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM stock has increased by 11.8% and is now trading at $138.70. View the best growth stocks for 2024 here. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our DXCM earnings forecast. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings results on Thursday, February, 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. The medical device company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.95% and a trailing twelve-month return on equity of 28.31%. The company's quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.34 earnings per share. Read the conference call transcript. What ETFs hold DexCom's stock? ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS). When did DexCom's stock split? DexCom's stock split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). Who are DexCom's major shareholders? DexCom's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.53%), Baillie Gifford & Co. (4.28%), Capital Research Global Investors (3.97%), Sands Capital Management LLC (3.91%), Capital World Investors (2.41%) and Artisan Partners Limited Partnership (1.53%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More This page (NASDAQ:DXCM) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.